NASDAQ: ALLRAllarity Therapeutics Inc Stock
$0.64-0.03 (-4.48%)
Updated May 17, 2024
ALLR Price
$0.64
Fair Value Price
-$0.57
Market Cap
$11.25M
52 Week Low
$0.63
52 Week High
$283.20
P/E
0x
P/B
-1.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.39M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.85
Operating Cash Flow
-$11M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALLR Overview
Allarity Therapeutics is a biopharma company developing oncology products and drugs for the personalized treatment of cancer. The company uses Drug Response Predictor (DRP®) technology to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures. Its pipeline products include Dovitinib, Stenoparib, Ixempra, and other formulations. Allarity was incorporated in 2004 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALLR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALLR ($0.64) is overvalued by 212.18% relative to our estimate of its Fair Value price of -$0.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALLR ($0.64) is not significantly undervalued (212.18%) relative to our estimate of its Fair Value price of -$0.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALLR due diligence checks available for Premium users.
Be the first to know about important ALLR news, forecast changes, insider trades & much more!
ALLR News
Valuation
ALLR fair value
Fair Value of ALLR stock based on Discounted Cash Flow (DCF)
Price
$0.64
Fair Value
-$0.57
Undervalued by
212.35%
ALLR ($0.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALLR ($0.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALLR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
8.47x
Market
30.97x
ALLR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.74x
Industry
6.01x
ALLR's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
ALLR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.0M
Liabilities
$18.4M
Debt to equity
-2.85
ALLR's short-term liabilities ($18.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALLR's short-term assets ($2.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALLR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALLR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$0.0
Financing
$1.4M
ALLR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALLR vs Biotech Stocks
Allarity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.